A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The EvolvE Study)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Eosinophilic Esophagitis
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Ability to read, understand, and provide written informed consent
    2. Documented diagnosis of Esophageal intraepithelial eosinophilic (EoE) by endoscopy
    3. Must be symptomatic, defined as:

You may not be eligible for this study if the following are true:

    1. Diagnosis of hypereosinophilic syndrome or Churg-Strauss syndrome (or eosinophilic granulomatosis with polyangiitis).
    2. History of a clinicopathologic diagnosis of eosinophilic gastritis or eosinophilic duodenitis.
    3. Known acti

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.